Tibotec

Tibotec

Industry	Pharmaceutical
Founded	1994;31 years ago (1994)
Founders	Rudi Pauwels Carine Claeys Marie-Pierre de Béthune Kurt Hertogs Hilde Azijn
Defunct	2002 (2002)
Fate	Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division
Website	tibotec.com

Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment.

The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium). ^[1]

History

In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002, ^[2] and was renamed Janssen Therapeutics in June 2011. ^[3]

Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda. ^{[4] [5]}

Drugs

• Darunavir (TMC114, tradename Prezista), a protease inhibitor
• Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
• Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug ^[6]
• Rilpivirine (TMC278, tradename Edurant), an NNRTI
• Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents. ^[7]
• Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

See also

• Galapagos NV

References

1. Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID   1689015. S2CID   4354080.
2. "Johnson & Johnson to Acquire Tibotec-Virco". Johnson & Johnson . 2002-03-22. Archived from the original on 2002-06-08. Retrieved 2023-05-16.
3. Van Houten, Pamela (2011-06-22). "Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies". Johnson & Johnson . Archived from the original on 2023-05-17. Retrieved 2023-05-17.
4. Schmickle, Sharon (2008-11-13). "University of Minnesota doctors battle AIDS in Uganda". MinnPost . Archived from the original on 2010-06-23. Retrieved 2023-05-16.
5. "Clinical Research at the Infectious Diseases Institute" (PDF). The Global Health Network. Infectious Diseases Institute. Archived (PDF) from the original on 2023-05-17. Retrieved 2023-05-17.
6. Andries, K.; Verhasselt, P; Guillemont, J; Göhlmann, H. W.; Neefs, J. M.; Winkler, H; Van Gestel, J; Timmerman, P; Zhu, M; Lee, E; Williams, P; De Chaffoy, D; Huitric, E; Hoffner, S; Cambau, E; Truffot-Pernot, C; Lounis, N; Jarlier, V (2005). "A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis". Science. 307 (5707): 223–7. Bibcode:2005Sci...307..223A. doi: 10.1126/science.1106753 . PMID   15591164. S2CID   33219841.
7. Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.

External links

• Tibotec